Search

Tasonermin

It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

Vinorelbine

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. … It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid.

Alosetron

Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. … Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women.

Cabotegravir

[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

1,2-Docosahexanoyl-sn-glycero-3-phosphoserine

Siponimod

[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

Esketamine

The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications

Anisotropine methylbromide

action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

Bemiparin

Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). … Interestingly, current research is underway for the potential benefit of bemiparin in the treatment of tumors and diabetic foot ulcers [L1468, A7866].